The short answer
Henry Meds is our top pick for switchers. Score 7.8 of 10. Pricing is a reported tier of $197/mo (shown at signup only, not published), month-to-month with online cancel, and a clinical model that accepts an existing dose without forcing you to re-titrate. A competitive path if you are exiting a program with rising prices or a multi-month lock-in.
What to know first
Patients who switch GLP-1 programs are typically optimizing for one of three things: lower monthly cost at maintenance dose, an exit from a 6 or 12-month commitment they regret, or a clinician who understands their tolerance and dose history. Switchers don't need a fast intake. They need a program that accepts dose-history documentation, prescribes at the dose they're already on without a forced re-titration, and prices the long run rather than the first month.
What we considered
- Maintenance-dose monthly cost (the bill that lands every month, not the headline starter price)
- Accepts existing dose without forced re-titration
- No lock-in (so a bad switch doesn't cost you 6 months)
- Pharmacy partner stability and disclosed continuity plan
- Speed from intake to first refill (most switchers can't afford a gap)
Some visit links earn us a commission.
Scores out of 10, equal-weighted across five dimensions. How we score
Top pick: Henry Meds
Henry Meds's reported $197/mo tier (shown at signup), online cancel and willingness to continue an existing dose without forced re-titration make it a strong switching path for compounded GLP-1 patients who want lower cost and less lock-in.
Read the full Henry Meds review →
Why Henry Meds won this category
Henry Meds wins on the metric that matters most for a switcher: competitive maintenance-dose pricing with no commitment. Pricing is a reported tier of $197/mo shown at signup (not published on the homepage). If you're switching from a program that priced your maintenance dose at $400 or $500, you roughly cut the bill in half without changing molecule. Mochi is the closest competitor at $178/mo month-to-month.
Henry's clinical model accepts existing dose history. If you're already on 1.7 mg semaglutide weekly, Henry's clinician will continue you at 1.7 mg rather than restart at 0.25 mg. That sounds like an obvious feature, but several programs in our chart treat every new patient as a new titration, which costs you 3 to 4 months of weight-loss progress while you re-climb the ladder. Verify this on the intake form before paying; the explicit question to ask is 'will you continue me at my current dose given my pharmacy fill history?'
The cancellation terms are clean. Month-to-month, online self-serve cancel, no prepay or non-refundable membership fee. If you switch to Henry and the pharmacy partner changes or supply is disrupted, you walk without a financial penalty. This matters in 2026 because compounded GLP-1 enforcement has tightened and the operating environment is fluid.
The trade-off, like Mochi, is the compounded medication path. Henry prescribes compounded semaglutide and tirzepatide from 503A pharmacies. If you're switching specifically because you want to move from compounded to branded, Henry is the wrong direction. For branded switchers, PlushCare or Form Health are the cleaner picks. For switchers staying on compounded but looking for lower monthly cost and no lock-in, Henry is the cleanest path.
Who this pick isn't for
Henry Meds is not the right pick if you're switching to escape compounded entirely. The Lilly lawsuits against compounded tirzepatide pharmacies through 2025 and the FDA's February 2025 semaglutide shortage resolution have made the regulatory exposure on compounded GLP-1s real. If you're switching specifically to brand Wegovy or Zepbound for regulatory clarity, look at Ro Body's $299 LillyDirect path or PlushCare's insurance-billed branded path.
Henry is also wrong if you're switching because your medical complexity outgrew the program you were on. Patients with new comorbidities (a recent T2D diagnosis, CV event, MASH workup) who need coordinated care across more than just the GLP-1 should switch to Knownwell or Form Health, not to another lightweight compounded program. The price is higher; the clinical depth justifies it.
And Henry isn't the right pick if your switch is driven by insurance coverage you just gained. If your new employer plan covers Wegovy or Zepbound with PA, you want PlushCare or Form Health, not cash-pay compounded. The PA paperwork takes 4 to 6 weeks but the monthly out-of-pocket lands at $25 to $50 rather than $197. Run the formulary check before assuming cash-pay is still your cheapest option.
Runner-up: Mochi Health
Mochi is roughly tied with Henry on price and lock-in terms, with a slight edge on clinical screening but a slight friction increase on intake. If Henry's pharmacy partner pool doesn't match your state, Mochi is the next call.
Read the full Mochi Health review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| Henry Meds | 8 | $297/mo | Month-to-month | 2 days |
| Mochi Health | 8.2 | $178/mo | Month-to-month | 3 days |
| Medvi | 7.8 | $299/mo | Month-to-month | 2 days |
Other strong picks
Frequently asked questions
Can I switch mid-titration without restarting at 0.25 mg?
How long can I afford to be off medication during the switch?
Will my new program write a different prescription than my old one?
Can I switch from compounded to brand?
What if my old program is still charging me?
Will the new program need new labs?
What's the cheapest path if I'm currently paying over $400 a month?
Sources
- Wadden TA, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
- Rubino D, et al. STEP 4: weight maintenance after semaglutide discontinuation. JAMA 2021
- FDA: declared resolution of semaglutide shortage, February 2025
Related
